![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Adherex Technologies, Inc. |
Information provided by: | Adherex Technologies, Inc. |
ClinicalTrials.gov Identifier: | NCT00225550 |
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that subjects can tolerate.
Condition | Intervention | Phase |
Neoplasms |
Drug: ADH -1 (Exherin™) |
Phase I Phase II |
MedlinePlus related topics: | Cancer |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment |
Official Title: | Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Daily for 5 Consecutive Days by Intravenous Infusion in Subjects With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX 01 003) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Adherex Technologies Inc. Corporate Homepage 
![]()   |
Study ID Numbers: | Adherex Protocol AHX-01-003 |
First Received: | September 22, 2005 |
Last Updated: | August 3, 2007 |
ClinicalTrials.gov Identifier: | NCT00225550 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
![]() |